Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients

Clinical Transplantation

Volumn 27, Issue 4, 2013, Pages 591-597

  Koppula, Sireesha ^a   Yost, Sarah E ^b   Sussman, Amy ^a   Bracamonte, Erika R ^a   Kaplan, Bruce ^a,c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Belatacept; Renal transplantation; Tacrolimus; Thrombotic microangiopathy

Indexed keywords

BELATACEPT; COTRIMOXAZOLE; FLUCONAZOLE; HAPTOGLOBIN; HLA ANTIBODY; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTERIOLE; ARTICLE; CASE REPORT; ERYTHROCYTE; GLOMERULUS CAPILLARY; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ARTERY; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY HEMORRHAGE; KIDNEY MALFORMATION; KIDNEY NECROSIS; KIDNEY TRANSPLANTATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MAINTENANCE THERAPY; MALE; PLASMAPHERESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; URINE VOLUME; VASCULITIS;

BELATACEPT; RENAL TRANSPLANTATION; TACROLIMUS; THROMBOTIC MICROANGIOPATHY;

FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS; THROMBOTIC MICROANGIOPATHIES;

EID: 84881528485     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12170     Document Type: Article

References (32)

1. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010: 10: 1517.
2. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009: 361: 1676.
3. Scheiring J, Rosales A, Zimmerhackl LB. Clinical practice. Today's understanding of the haemolytic uremic syndrome. Eur J Pediatr 2010: 169: 7.
4. Besbas N, Karpman D, Landau D et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006: 70: 423.
5. Ferraris JR, Ramirez JA, Ruiz S et al. Shiga toxin-associated hemolytic uremic syndrome, absence of recurrence after renal transplantation. Pediatr Nephrol 2002: 17: 809.
6. Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 2003: 18: 1095.
7. Bresin E, Daina E, Noris M et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006: 1: 88.
8. Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: the impact of MCP CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006: 108: 1267.
9. Kavanagh D, Goodship TH. Membrane cofactor protein and factor I: mutations and transplantation. Semin Thromb Hemost 2006: 32: 155.
10. Andreoni KA, Brayman Kl, Guidinger MK, Sommers CM, Sung RS. Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant 2007: 7: 1359.
11. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009: 4: 481.
12. Ramzy D, Rao V, Tumiati LC et al. Role of endothelin-1 and nitric oxide bioavailability in transplant related vascular injury: comparative effects of rapamycin and cyclosporine. Circulation 2006: 114(Suppl.): 1214.
13. Ponticelli C. De novo thrombotic microangiopathy. An underrated complication of renal transplanatation. Clin Nephrol 2007: 67: 335.
14. Ruggenenti P. Post-transplant hemolytic uremic syndrome. Kidney Int 2002: 62: 1093.
15. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Kidney Int 2001: 60: 831.
16. Al-Massarani G, Vacher-Coponat H, Paul P et al. Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. Am J Transplant 2008: 8: 2360.
17. Noris M, Bucchioni S, Galbusera M et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 2005: 16: 1177.
18. Nilsson SC, Karpman D, Vaziri-Sani F et al. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol 2007: 44: 1835.
19. Racusen LC, Haas M. Antibody-mediated rejection in renal allografts: lessons from pathology. Clin J Am Soc Nephrol 2006: 1: 415.
20. Le Quintret M, Lionet A, Kamar N et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008: 8: 1694.
21. Noone D, Al-Matrafi J, Tinckam K et al. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012: 12: 2546.
22. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009: 360: 544.
23. Nürnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009: 360: 542.
24. Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, Lozano M. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010: 89: 903.
25. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Frémeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011: 7: 23.
26. Ashman N, Chapagain A, Dobbie H et al. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. Am J Transplant 2009: 9: 424.
27. Fortin MC, Raymond MA, Madore F et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporine-sirolimus combination. Am J Transplant 2004: 4: 946.
28. Robson M, Cote I, Abbs I, Koffman G, Goldsmith D. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 2003: 3: 324.
29. Sartelet H, Toupance O, Lorenzato M et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005: 5: 2441.
30. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008: 358: 1129.
31. Karthikeyan V, Parasuraman R, Shah V et al. Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplant. Am J Transplant 2003: 3: 1289.
32. Midtvedt K, Bitter J, Dørje C, Bjørneklett R, Holdaas H. Belatacept as immunosuppression in patient with recurrence of hemolytic uremic syndrome after renal transplantation. Transplantation 2009: 87: 1901.